Gravity Analytica

Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024

VXRT 10.24.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-10-28

Name of Upcoming Event:World Vaccine Congress Europe 2024

Full Press Release SEC Filings Our VXRT Tweets

About Gravity Analytica

Recent Filings

PDF Version

SOUTH SAN FRANCISCO, Calif.,Oct. 24, 2024(GLOBE NEWSWIRE) --Vaxart, Inc.(Nasdaq: VXRT) today announced that it will present research featuring its COVID-19 and norovirus oral pill vaccine candidates at the World Vaccine Congress Europe 2024 taking place inBarcelona, SpainonOctober 28-31, 2024.

Vaxart’s mission is to improve global public health by developing a transformative oral tablet vaccine platform. With multiple promising clinical-stage programs, including those targeting COVID-19 and norovirus, the Company is committed in solving serious health challenges facing society. Vaxart’s differentiated platform has generated both systemic and mucosal immune responses and demonstrated a favorable safety and tolerability profile in clinical trials, reinforcing its potential of bringing worldwide game changing solutions.

Presentation Information:

Title:Oral Covid Vaccine - Clinical Update from Phase 1 to Phase 2BSpeaker:Dr.James F. Cummings, Chief Medical OfficerDate:Tuesday, October 29Time:3:55 p.m. CETLocation: Theatre 3

Title:Oral Norovirus Vaccine Induces Cross-reactivity and Protection Against Infection in HumansSpeaker:Dr.Sean Tucker, Founder and Chief Scientific OfficerDate:Wednesday, October 30Time:11:40 a.m. CETLocation: Theatre 5

AboutVaxart

Vaxartis a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform.Vaxartvaccines are designed to be administered using pills that can be stored and shipped without refrigeration and to eliminate the risk of needle-stick injury.Vaxartbelieves that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication.Vaxarthas filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact

Vaxart Media and Investor RelationsMatt SteinbergFINN PartnersIR@vaxart.com(646) 871-8481

Source: Vaxart, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com